Skip to main content
. 2017 Feb 11;32(Suppl 2):ii106–ii112. doi: 10.1093/ndt/gfw287

FIGURE 2.

FIGURE 2

HR of mortality in the US DOPPS versus Europe DOPPS, with and without adjustment for differences in facility vascular access (VA) use in DOPPS phases 1–2 (1996–2004). The HR of mortality for HD patients in the US versus Europe (n = 24 398) stratified by study phase is shown on the left, adjusted for patient age, sex, black race, number of years with end-stage renal disease, body weight, 14 summary comorbid conditions, whether treated in a hospital-based unit, facility median treatment time, facility % patients with serum phosphorus >5.5 mg/dL and facility % patients with serum calcium >10 mg/dL; and, on the right, additionally adjusted for % facility vascular access use. All models accounted for facility clustering effects. Europe refers to France, Germany, Italy, Spain and the United Kingdom. Adapted with permission from Pisoni et al. [6].